Darvocet Lawsuit | Darvocet Litigation | Darvocet Class Action

Growing, Ongoing Darvocet Litigation

Sarah Klein | March 25th, 2011 | Posted in Darvocet Lawsuit News

Since the FDA issued the ban on all drugs containing propoxyphene at the end of 2010, thousands who have suffered or lost loved ones due to the pain-killing drugs have joined Darvocet litigation at a rapid rate.

Drug manufacturers enjoyed 53 years of propoxyphene profits at the expense of consumers who were told that Darvon, Darvocet, and other generic offerings presented little relative risk. Despite consumer protection groups lobbying decades for a recall, and black-box warnings of heart abnormalities like arrhythmia and sudden death, the FDA repeatedly concluded that the risk-benefit analysis tilted in favor of continued use.

After a recent study conclusively established evidence to the contrary, the FDA suddenly announced the Darvocet ban prompting an equally sudden onslaught of Darvocet lawsuit filings.

New Yorker kicks off trend of nationwide Darvocet litigation

Kristine Esposito became one of the first plaintiffs to file an individual lawsuit. A native of New York, Esposito was only 31 years old when she developed heart arrhythmia while taking Darvocet. As a result of her condition, Esposito was forced to undergo a surgical procedure in an (successful) effort to save her life. She is seeking $10 million in damages.

The Darvocet lawyer handling Esposito’s claim filed papers with the Judicidal Panel on Multidistrict Litigation seeking an order to consolidate all federal Darvocet, Darvon, and generic propoxyphene lawsuits into the US District Court for the Eastern District of New York. That hearing is currently set for the end of March.

Darvocet litigation heads south to Lousiana

On March 4, 2011, Billy Lambert, Gladys Delaune and Margaret Seagraves filed a Darvocet lawsuit in U.S. District Court for the Eastern District of Louisiana against defendants: Xanodyne Pharmaceuticals, Inc.; generic makers of propoxyphene drugs including Teva Pharmaceuticals USA Inc., Qualitest Pharmaceuticals, Inc.,; and previous Darvocet manufacturers, AAIPharma Services and Eli Lilly and Co.

The lawsuit alleges that the plaintiffs have all developed serious heart problems as a side effect of Darvocet use. One such heart problem is wide complex tachycardia, a potentially life threatening cardiac arrhythmia. This particular form of arrhythmia originates in the ventricles and causes an abnormal, increased resting heartbeat.

Darvocet class action lawsuit

In December 2010, Linda Gallagher became the representative plaintiff in a Darvocet class action filed in the federal court of Louisiana. Gallagher alleges that Xanodyne Pharmaceuticals, maker of the painkiller in question, failed to provide adequate warnings about the risks associated with Darvocet, a potentially deadly combination of propoxyphene and acetaminophen. As a result, Gallagher suffered two heart attacks. She and other members of the Darvocet class action are seeking damages for past and continuing medical expenses, lost earnings, diminished quality of life, pain and suffering, and other compensable claims.

Darvocet wrongful death lawsuit

A wrongful death Darvocet lawsuit was filed in Ohio federal court by the parents of 22-year-old Kira Nicole Gilbert, who died eight days after her Darvocet treatment began. The wrongful death lawsuit was filed against Xanodyne Pharmaceuticals Inc., the former distributor of Darvon and Darvocet, and Eli Lilly and Co., the company that originally manufactured Darvon and Darvocet.

Gilbert was prescribed Darvocet as a mild painkiller after a knee injury. Reports indicate that her death was due to an acute cardiac failure with evidence of fluid buildup in the lungs. Kira had no previous medical history of any heart related conditions.

With its long history and widespread use, Darvocet and its propoxyphene relatives have left a long trail of sickness and death in their hazardous wake leaving little choice for many than to seek the advice of a Darvocet lawyer and join the litigation.